Vol. 5 No. 1 (2018): January-December 2018

DOI: https://doi.org/10.1177/2284240318807726

Published: 2018-12-31

Original Research Articles

Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group

Francesco S. Mennini, Raffaella Viti, Chiara Bini, Andrea Marcellusi, Fabio Palazzo
- PDF
Burden of disease, healthcare pathways and costs of cardiovascular high-risk patients with type 2 diabetes: a real world analysis L’onere della malattia, risorse sanitarie e costi dei pazienti con diabete di tipo 2 ad elevato rischio cardiovascolare: un’analisi “real world”

Carlo Piccinni, Letizia Dondi, Giulia Ronconi, Antonella Pedrini, Nello Martini, Giulio Marchesini
- PDF
Assessing social and economic impact of subcutaneous mAbs in oncology

Americo Cicchetti, Silvia Coretti, Daniele Mascia, Nicola Mazzanti, Pietro Refolo, Francesca R. Rolli, Filippo Rumi1
- PDF
A comparative examination of healthcare use related to hearing impairment in Europe

Mimi Xiao, Ciaran O’Neill
- PDF
Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia

Elena P. Lanati, Paola La Malfa, Arianna Iorio, Francesco S. Mennini, Francesca Fanelli, Sandro Gentile
- PDF
Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto

Mennini FS, Pisanti P, Terzoni S, Lanati EP, Marcellusi A, Marcelli A, Iorio A
- PDF
Analisi di budget impact del biosimilare di etanercept: lo scenario italiano

Roberto Ravasio, Giampiero Girolomoni, Roberto Gorla
- PDF
Patients’ Associations and HTA for medicines: actual and future role in Italy

Claudio Jommi, MSc, Arianna Bertolani, Phd
- PDF
The economic impact of the correct insulin injection technique associated with the use of 4 mm 32G needles in the treatment of patients with type 2 diabetes

Roberto Ravasio, Giorgio Grassi
- PDF
The hospitalization burden of influenza: just the tip of the iceberg?

Arianna Bertolani, Giovanni Fattore, Fabrizio Pregliasco
- PDF
Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in Italy

Sanja Stanisic, Alessia Marocco, Anna Gallo, Paolo Rama, Marta Sacchetti, Maurizio Rolando, Augusto Pocobelli, Roberto Ceccuzzi, Andrea Leonardi, Rita Mencucci, Emilio Pedrotti, Elisa Postorino, Maurizio Mascia, Lucia R Mazzamuto, Luisanna Prisco, Floortje Van Nooten, Patrizia Berto
- PDF
Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective

Alessia Marocco, Sanja Stanisic, Francesca Fanelli, Francesco Damele, Furio Colivicchi
- PDF
Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives

Carla Rognoni, Arianna Bertolani, Claudio Jommi
- PDF
Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) study

Carlo Lazzaro, Fabiano Di Marco, Nicola Scichilone, Fulvio Braido, Marco Contoli, Paola Rogliani, Pierachille Santus, Valentina Acciai, Carla Scognamillo, Irene Olivi, Angelo Guido Corsico
- PDF
Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia

Sanja Stanisic, Americo Cicchetti, Camillo Porta, Giuseppe Procopio, Patrizia Berto
- PDF
Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy

Roberto Ravasio, Silvia Antonelli, Veronica Rogai, Walid Fakhouri, Jean Philippe Capron, Serena Losi
- PDF
Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA

Federico Villa, Claudio Jommi, Armando Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini
- PDF
Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco

Dario Lidonnici, Virginia Ronco, Martina Isernia, Elena Lanati, Claudio Jommi, Pier Luigi Canonico, Armando A. Genazzani
- PDF
I costi dei pazienti con patologie infiammatorie dell’intestino (Malattia di Crohn e colite ulcerosa). Studio real world in Italia

Stefano Capri, Antonio Russo
- PDF
Il trattamento con farmaci intravitreali anti-VEGF in pazienti naïve in Italia

Albrecht M, Nica M, Colombo D, Ferri C, Tadini P, Introini U, Bandello F
- PDF
Evaluación del impacto presupuestario del servicio integral de asistencia domiciliaria nutricional

Javier Nuñez Alfonsel, Benedetto Ielpo, Villareal García-Lomas M, Cristóbal Belda Iniesta
- PDF
Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study

Andrea Aiello, Daniela Ritrovato, Claudia Pitotti
- PDF
A budget impact analysis of a clinical medication review of patients in an Irish university teaching hospital

Alan Kearney, Elaine K Walsh, Ann Kirby, Ciaran Halleran, Derina Byrne, Jennifer Haugh, Laura J Sahm
- PDF

Erratum

Corrigendum
- PDF

Vol. 5 No. 1 (2018): January-December 2018

Original Research Articles

Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group

Burden of disease, healthcare pathways and costs of cardiovascular high-risk patients with type 2 diabetes: a real world analysis L’onere della malattia, risorse sanitarie e costi dei pazienti con diabete di tipo 2 ad elevato rischio cardiovascolare: un’analisi “real world”

Assessing social and economic impact of subcutaneous mAbs in oncology

A comparative examination of healthcare use related to hearing impairment in Europe

Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia

Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto

Analisi di budget impact del biosimilare di etanercept: lo scenario italiano

Patients’ Associations and HTA for medicines: actual and future role in Italy

The economic impact of the correct insulin injection technique associated with the use of 4 mm 32G needles in the treatment of patients with type 2 diabetes

The hospitalization burden of influenza: just the tip of the iceberg?

Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in Italy

Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective

Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives

Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) study

Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia

Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy

Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA

Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco

I costi dei pazienti con patologie infiammatorie dell’intestino (Malattia di Crohn e colite ulcerosa). Studio real world in Italia

Il trattamento con farmaci intravitreali anti-VEGF in pazienti naïve in Italia

Evaluación del impacto presupuestario del servicio integral de asistencia domiciliaria nutricional

Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study

A budget impact analysis of a clinical medication review of patients in an Irish university teaching hospital

Erratum

Corrigendum

Browse

banners150

Vol. 5 No. 1 (2018): January-December 2018

Original Research Articles

Erratum

Sign up

Browse

banners150